Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.51 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TPI1 | P60174 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646067 | 0.89 | ERN1 (0.51) | ERN1PELI1PTPN1ALDH1A1CYP1A2 | |
| SCHEMBL15645938 | 0.85 | ERN1 (0.48) | ERN1PELI1CYP3A4CLK4 | |
| SCHEMBL15645545 | 0.83 | ERN1 (0.63) | ERN1PELI1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15646708 | 0.80 | ERN1 (0.48) | ERN1PELI1PTPN1 | |
| SCHEMBL20030216 | 0.80 | ERN1 (0.47) | ERN1PELI1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15645548 | 0.80 | ERN1 (0.46) | ERN1PELI1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15646561 | 0.79 | ERN1 (0.48) | ERN1PELI1PTPN1 | |
| SCHEMBL21654599 | 0.79 | KDM4E (0.47) | ERN1PELI1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19153822 | 0.78 | ERN1 (0.43) | ERN1PTPN1ALDH1A1MEN1LMNA | |
| SCHEMBL96128 | 0.78 | ERN1 (0.51) | ERN1PELI1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | INSTITUT PASTEUR KOREA (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ST PHARM CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2776432-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2776432-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| WO-2013066684-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ZC3HAV1, ZC3HAV1L, HAVCR2 | ERN1 1948/4885PELI1 2916/4885PTPN1 747/4885 |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ERN1 572/4885PELI1 1296/4885PTPN1 455/4885 |
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | ZC3HAV1, ZC3HAV1L, HAVCR2 | ERN1 2158/4885PELI1 3037/4885PTPN1 827/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | ERN1 572/4885PELI1 1296/4885PTPN1 455/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | ERN1 572/4885PELI1 1296/4885PTPN1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.